Eli Lilly and Company and Mesoblast Limited: SG&A Spending Patterns Compared

Eli Lilly vs. Mesoblast: SG&A Spending Insights

__timestampEli Lilly and CompanyMesoblast Limited
Wednesday, January 1, 2014662080000054170000
Thursday, January 1, 2015653300000065378000
Friday, January 1, 2016645200000052263000
Sunday, January 1, 2017658810000035072000
Monday, January 1, 2018597510000027415000
Tuesday, January 1, 2019621380000036983000
Wednesday, January 1, 2020612120000050918000
Friday, January 1, 2021643160000063586000
Saturday, January 1, 2022644040000057967000
Sunday, January 1, 2023694120000053107000
Monday, January 1, 2024859380000023626000
Loading chart...

Unlocking the unknown

SG&A Spending Patterns: A Tale of Two Companies

In the world of pharmaceuticals, strategic spending on Selling, General, and Administrative (SG&A) expenses can be a key differentiator. Eli Lilly and Company, a titan in the industry, has consistently invested heavily in SG&A, with an average annual expenditure of approximately $6.4 billion over the past decade. This investment underscores their commitment to maintaining a robust market presence and operational efficiency.

In contrast, Mesoblast Limited, a smaller player, has averaged around $47 million annually in SG&A expenses. This stark difference highlights the varied strategies employed by companies of different scales. Interestingly, both companies have shown a downward trend in SG&A spending, with Mesoblast reducing its expenses by nearly 56% from 2014 to 2023.

These spending patterns offer a glimpse into the strategic priorities of these companies, reflecting their unique approaches to growth and market competition.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025